The Business Research Company’s report on the Beovu (Brolucizumab) Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
#How have key drivers contributed to the rapid growth of the beovu (brolucizumab) market?
The rising prevalence of age-related macular degeneration (AMD) is expected to drive the expansion of the beovu (brolucizumab) market going forward. Age-related macular degeneration (AMD) is a progressive eye condition that causes vision loss in the central field of vision, primarily in older adults. The aging population is growing due to factors such as increased life expectancy, declining birth rates, and advancements in healthcare. Beovu (brolucizumab) is used in the treatment of age-related macular degeneration (AMD) to reduce vision loss by targeting and inhibiting vascular endothelial growth factor (VEGF), improving retinal health. For instance, in March 2023, according to a report by the BrightFocus Foundation, a US-based nonprofit organization, around 200 million people globally are affected by AMD, with this number projected to rise to 288 million by 2040. Therefore, the rising prevalence of age-related macular degeneration (AMD) will fuel the growth of the beovu (brolucizumab) market.
Access Your Free Sample of the Global Beovu (Brolucizumab) Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19994&type=smp
How has the beovu (brolucizumab) market size evolved, and what are the latest forecasts for its expansion?
The beovu (brolucizumab) market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to the rising prevalence of age-related macular degeneration (AMD), increasing healthcare expenditure, awareness campaigns for age-related macular degeneration (AMD) management, government support for innovative treatments, and growing adoption of precision imaging technologies.
The beovu (brolucizumab) market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the increasing aging global population, rising demand for targeted biologics, expansion of healthcare infrastructure, favorable reimbursement policies for AMD therapies, and growing emphasis on personalized medicine. Major trends in the forecast period include a shift toward biosimilar development, growth in telemedicine for AMD care, adoption of AI-based diagnostic tools, emphasis on sustainability in drug manufacturing, collaboration between biotech firms and tech companies, and product innovation.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=19994&type=smp
Which major companies dominate the beovu (brolucizumab) market?
Major companies operating in the beovu (brolucizumab) market include Novartis AG
What trends will shape the future of the beovu market?
The key trend in the beovu (brolucizumab) market is the focus on developing innovative solutions to expand treatment options and market reach. Companies are actively working on gaining approvals for additional indications, such as diabetic macular edema (DME), to enhance the therapeutic potential. Beovu, used to treat retinal diseases such as wet age-related macular degeneration (AMD) and DME, works by inhibiting VEGF-A to reduce abnormal blood vessel growth and prevent vision loss. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced the European Commission (EC) has approved Beovu (brolucizumab) 6 mg to treat visual impairment caused by diabetic macular edema (DME). This approval marks Beovu’s second indication from the EC, following its initial approval in 2020 for the treatment of wet age-related macular degeneration. The EC’s decision applies to all 27 EU member states, as well as Iceland, Norway, and Liechtenstein.
Which region dominates the beovu (brolucizumab) market, and what factors contribute to its leadership?
North America was the largest region in the beovu (brolucizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the beovu (brolucizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/beovu-brolucizumab-global-market-report
How is the beovu (brolucizumab) market segmented, and which segment holds the largest share?
The beovu (brolucizumab) market covered in this report is segmented –
1) By Indication: Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Other Retinal Disorders
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Specialty Clinics, Ambulatory Surgical Centers
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19994
What defines the structure and scope of the beovu (brolucizumab) market?
Brolucizumab, marketed as Beovu, is a monoclonal antibody used to treat retinal diseases such as wet age-related macular degeneration (AMD). It works by inhibiting vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and fluid leakage in the retina. Beovu offers a less frequent dosing schedule compared to other VEGF inhibitors.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
